<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161148</url>
  </required_header>
  <id_info>
    <org_study_id>PBPSC</org_study_id>
    <nct_id>NCT00161148</nct_id>
  </id_info>
  <brief_title>Probiotics in Patients With Primary Sclerosing Cholangitis</brief_title>
  <official_title>Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      PSC is a progressive liver disease without effective medical treatment. There is often&#xD;
      co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to&#xD;
      benefit patients with ulcerative colitis. In the current protocol potential beneficial&#xD;
      effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being&#xD;
      assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics,&#xD;
      1 one wash-out and 3 months placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I. INTRODUCTION Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver&#xD;
      disease characterized by multifocal strictures of intrahepatic and extrahepatic bile ducts,&#xD;
      which frequently leads to biliary cirrhosis and liver failure. The aetiology of PSC is&#xD;
      unknown but is thought to be (auto)immune-mediated. Nevertheless, in a number of randomized&#xD;
      controlled trials a clear benefit of treatment with various immunosuppressive agents, such as&#xD;
      D-penicillamine, methotrexate, corticosteroids or nicotine, could not be demonstrated.&#xD;
      Although treatment with ursodeoxycholic acid (UDCA) improves serum liver tests and is&#xD;
      prescribed on a large scale for PSC patients, this therapeutic modality may have no&#xD;
      beneficial effect on the course of the disease.&#xD;
&#xD;
      70 - 90% of patients with PSC have concurrent inflammatory bowel disease (IBD), mostly&#xD;
      ulcerative colitis. Conversely, 7% of patients with IBD have PSC. The close association&#xD;
      between inflammatory bowel disease and PSC suggests that substances originating from the&#xD;
      inflamed gut may damage the liver and biliary tree. Bacterial products may act as toxic&#xD;
      proinflammatory agents. N-formyl L-methionine L-leucine L-tyrosine is a peptide produced by&#xD;
      enteric flora. When this peptide was introduced into the colon of rats with colitis, it was&#xD;
      absorbed, underwent enterohepatic circulation, and appeared undegraded in bile. Histologic&#xD;
      changes in the livers of the rats resembled those in PSC.&#xD;
&#xD;
      Probiotics are beneficial bacteria that are used to redress the bacterial composition of the&#xD;
      enteric flora which may be altered in disease. Beneficial effects of probiotics have already&#xD;
      been described in diseases such as inflammatory bowel disease, pouchitis and non-alcoholic&#xD;
      fatty liver disease. Probiotic bacteria have also been shown to counteract inflammatory&#xD;
      processes by enhancing the degradation of enteral antigens, reducing the secretion of&#xD;
      inflammatory mediators, thereby modifying in a beneficial way the balance between pro- and&#xD;
      anti-inflammatory mediators, and stabilizing gut barrier functions. These effects may benefit&#xD;
      PSC patients.&#xD;
&#xD;
      Our hypothesis is that administration of probiotics may improve the composition of the&#xD;
      enteric flora and subsequently decrease the release of substances that may be toxic and&#xD;
      harmful for the liver and biliary tree in PSC patients. Furthermore, immunological&#xD;
      alterations induced by treatment with probiotics may have positive effects in PSC.&#xD;
&#xD;
      II. AIM OF THE STUDY Primary aim: assessment of the effects of treatment with probiotics on&#xD;
      serum liver tests.&#xD;
&#xD;
      Secondary aim: assessment of the effects of treatment with probiotics on fatigue and&#xD;
      pruritus.&#xD;
&#xD;
      III. DESIGN OF THE STUDY Double-blind randomized cross-over pilot study. Eligible patients&#xD;
      will be randomized to treatment with probiotics or placebo for a period of 12 weeks. After a&#xD;
      wash-out period of 4 weeks, placebo-treated patients will receive verum and vice versa for&#xD;
      another period of 12 weeks.&#xD;
&#xD;
      Dosage of concurrent medication for PSC (UDCA, immunosuppressives) will remain the same&#xD;
      during the entire study period.&#xD;
&#xD;
      Patients who are being treated with antibiotics during the study period for more than 1 week&#xD;
      will be withdrawn from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date>May 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the effects of treatment with probiotics on serum liver tests</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effects of treatment with probiotics on fatigue and pruritus</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotics</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PSC based on characteristic findings on cholangiography, or based on the&#xD;
             triad: typical histological findings in a liver biopsy, elevated serum alkaline&#xD;
             phosphatase and presence of inflammatory bowel disease&#xD;
&#xD;
          -  Presence of inflammatory bowel disease&#xD;
&#xD;
          -  elevated serum alkaline phosphatase&#xD;
&#xD;
          -  age â‰¥ 18 years&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  use of probiotics within one month before the study&#xD;
&#xD;
          -  use of antibiotics within one month before the study&#xD;
&#xD;
          -  a history of bacterial cholangitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel v Erpecum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karel v Erpecum, MD, PhD</last_name>
    <phone>+31 30 2506275</phone>
    <email>k.j.vanerpecum@azu.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Vleggaar, MD, PhD</last_name>
    <phone>+ 31 30 2506275</phone>
    <email>f.vleggaar@azu.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel v Erpecum, MD, PhD</last_name>
      <phone>+31 302506275</phone>
      <email>k.j.vanerpecum@azu.nl</email>
    </contact>
    <investigator>
      <last_name>Karel v Erpecum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004 May;39(5):1441-9.</citation>
    <PMID>15122774</PMID>
  </reference>
  <reference>
    <citation>Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997 Mar 6;336(10):691-5.</citation>
    <PMID>9041099</PMID>
  </reference>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 8, 2007</last_update_submitted>
  <last_update_submitted_qc>January 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2007</last_update_posted>
  <keyword>PSC</keyword>
  <keyword>Liver biochemistry</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

